RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT

NCT03412266 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: Cytarabine

Sponsor

Peking University People's Hospital